Counting the true cost of antiplatelet therapy for stroke prevention.
Morton
James A
JA
The Stroke Unit, Sunderland Royal Hospital, Sunderland, UK.
Newton
Julia
J
Gray
Christopher S
CS
D000368:Aged; D001241:Aspirin / Q000191:economics / Q000627:therapeutic use*; D000068342:Aspirin, Dipyridamole Drug Combination; D000077144:Clopidogrel; D003362:Cost-Benefit Analysis; D004176:Dipyridamole / Q000191:economics / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000191:economics; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000191:economics / Q000627:therapeutic use*; D055502:Secondary Prevention; D020521:Stroke / Q000188:drug therapy / Q000191:economics / Q000517:prevention & control*; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D006113:United Kingdom
D000068342:Aspirin, Dipyridamole Drug Combination; D004338:Drug Combinations; D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin